In 2009, Dr. Hua used the mild SMA models of Taiwanese mice to construct a severe SMA model that was more suitable for drug screening (50% SMA mice per litter, with an average lifespan of 10 days) and developed a monoclonal antibody that could specifically recognize human SMN protein which laid the foundation for animal experiments (Hua et al., 2010, 2011). The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.